PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles (FLEX): A real-world dataset and investigator-initiated protocols in ESBC
Publication: St. Gallen Authors: Jennifer A. Crozier, Lisa Blumencranz, Miranda Kleijn, Heather Kling, Amy M. Truitt, Darina Proni, Christine Finn, William Audeh, Bastiaan van der Baan, FLEX Investigators’ Group Background: The personalized management of early-stage breast cancers is enhanced by the ability of genomic signatures to stratify tumors into Read More
5-year distant metastasis-free survival outcomes on the pre-operative use of MammaPrint and BluePrint for neoadjuvant decisions in the NBREaST II trial
Publication: St. Gallen Authors: E. Göker, M.P. Hendriks, M. van Tilburg, A. Barcaru, L. Mittempergher, A. van Egmond, M. Kleijn and D. Generali Background: The 80-gene signature BluePrint® (BP) discriminates between three distinctive molecular subtypes: Luminal-type, HER2-type and Basal-type.1 Combined with the 70-gene signature MammaPrint® (MP), BP can further stratify Read More
Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens
Publication: St Gallen Authors: M. Kleijn, J. McKelley, J. Wei, B. Hoxeng, A. Menicucci, S. Wang, T. van Dalen, H. Horlings, W. Audeh Background: Pre-operative/neoadjuvant treatment utilization in early-stage breast cancer has been increasing, particularly during the COVID-19 pandemic. ESMO and ASCO guidelines note that genomic testing on Read More
Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients
Publication: Miami Breast Authors Pat Whitworth, James V Pellicane, Jr., Paul Baron, Peter Beitsch, Laura Lee, Angela Mislowsky, Carrie Dul, Paul Richards, Mark Gittleman, Stephanie Akbari, Shiyu Wang, Andrea Menicucci, Lisa Blumencranz, William Audeh, NBRST Investigators Group. Background Increased use of multi-gene expression profiling has enabled refinement Read More
The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer
Publication: Miami Breast Authors: Pat Whitworth, Jennifer A. Crozier, Robert Maganini, Cathy Graham, Beth-Ann Lesnikoski, Kathryn Wagner, June Lee, Julian Berrocal, Amy M. Truitt, Erin Yoder, Lisa Blumencranz, Bastiaan van der Baan, William Audeh, FLEX Investigators’ Group Background: Genomic expression profiles have implications for the personalized treatment of breast cancer Read More
Racial disparities within Basal-type breast cancer: clinical and molecular features of African American and Caucasian obese patients
PUBLICATION: SABCS 2020 AUTHORS: Dipali Sharma, Lisa E. Blumencranz, Heather M. Kling, Sahra Uygun, Sarah Untch, William Audeh, Jennifer A. Crozier, Mehran Habibi, and Raquel Nunes Background: African American breast cancer (BC) patients (AA) are diagnosed at a younger age and present more frequently with triple-negative/Basal tumors than Caucasian Read More
Molecular profiles and clinical-pathological features of Asian early-stage breast cancer patients
PUBLICATION: SABCS 2020 AUTHORS: Margaret Chen, Ava Kwong, Carolyn Hendricks, Nina D'Abreo, Laura Lee, Hatem H. Soliman, Charles Cox, Heather M. Kling, Midas M. Kuilman, Rajith Bhaskaran, Shiyu Wang, Andrea Menicucci, Sarah Untch, William Audeh, FLEX Investigators Group Background: Breast cancer incidence in Asian populations has increased in recent years Read More
